医学
滤泡性淋巴瘤
淋巴瘤
耐火材料(行星科学)
CD19
肿瘤科
卵泡期
嵌合抗原受体
CD20
内科学
抗原
美罗华
B细胞
单克隆
单克隆抗体
免疫学
癌症研究
抗体
癌症
免疫疗法
天体生物学
物理
作者
Ugo Testa,Del Francesco,Elvira Pelosi,Germana Castelli,Giuseppe Leone
标识
DOI:10.4084/mjhid.2024.012
摘要
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI